Crescent Biopharma, Inc. (CBIO) delivered a return of 10.48% over the past year. Since CBIO does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in Crescent Biopharma, Inc. one year ago would be worth $11,048 today, representing a gain of $1,048.

Crescent Biopharma, Inc. (CBIO) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For CBIO, the total return equals the price-only return.

No, Crescent Biopharma, Inc. (CBIO) underperformed the S&P 500 by 12.20 percentage points over the past year. CBIO delivered a total return of 10.48%, compared to the S&P 500's 22.68%. This means a passive S&P 500 index fund outperformed CBIO by 12.20pp during this period.

Crescent Biopharma, Inc. (CBIO) experienced a maximum drawdown of -54.98% over the past year, declining from its peak on 2025-06-25 to its trough on 2026-02-13. The stock recovered to its prior peak by 2026-03-31. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are Crescent Biopharma, Inc. (CBIO)'s long-term returns with dividends reinvested. Over 10 years, the total return is -97.7% (-31.3% CAGR) — $10,000 would have grown to $233. Over 20 years: -98.0% total return (-17.7% CAGR) — $10,000 → $204. Over 30 years: -98.0% total return (-12.2% CAGR) — $10,000 → $204. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Crescent Biopharma, Inc.'s best calendar year was 2017 with a total return of 167.8%. Its worst year was 2024 with a total return of -90.8%. This range shows the volatility investors should expect — the difference between the best and worst year is 258.6 percentage points.